Last reviewed · How we verify
mikostatin
Mikostatin, marketed by Zekai Tahir Burak Women's Health Research and Education Hospital, holds a unique position in its therapeutic segment, though specific revenue figures are not disclosed. The drug's key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential market protection. The primary risk lies in the lack of detailed clinical trial results and primary indication data, which may limit its competitive edge against other established therapies.
At a glance
| Generic name | mikostatin |
|---|---|
| Sponsor | Zekai Tahir Burak Women's Health Research and Education Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants (PHASE4)
- Comparison of Saccharomyces Boulardii and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mikostatin CI brief — competitive landscape report
- mikostatin updates RSS · CI watch RSS
- Zekai Tahir Burak Women's Health Research and Education Hospital portfolio CI